AstraZeneca recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer.

Earlier this year, AstraZeneca took Imfinzi to new heights in muscle-invasive bladder cancer (MIBC) with an FDA nod that made it the first immunotherapy cleared to treat patients both before and ...

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug prices sent shares of pharmaceuticals companies lower across the ...

AstraZeneca has a better P/E ratio of 27.25 than the aggregate P/E ratio of 27.19 of the Pharmaceuticals industry. Ideally, one might believe that AstraZeneca Inc. might perform better in the ...

A Google Translate screenshot correctly shows that the name of the pharmaceutical company AstraZeneca, when written as “A stra ze neca,” means “a road to death” in Latin. We reached out to ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

On Thursday, May 8, 2025, a three-judge panel of the Third Circuit affirmed the district court’s rejection of AstraZeneca’s constitutional and regulatory challenge to the Negotiation Program.

(Alliance News) - AstraZeneca PLC on Tuesday said it has completed its acquisition of Belgian biotechnology firm EsoBiotec SA, bolstering its cell therapy capabilities with a platform that could ...

The AstraZeneca (LSE: AZN) share price slumped 5% when the market opened on Monday (12 May). Fellow UK pharma giant GSK dipped too, losing 3.5% in early trading. Both regained a bit, with AstraZeneca ...